What This Bill Does · Plain English
Summary
Plain-English summary not yet available for this bill. Check back after our next analysis run.
Frequently Asked Questions
Did HR.6130 pass?
HR.6130 is still alive. Current stage: COMMITTEE. Pass likelihood: pending.
Who sponsored HR.6130?
HR.6130 was sponsored by Vern Buchanan (R-Florida).
Full Bill Text
119 HR 6130 IH: Alzheimer’s Screening and Prevention Act of 2025 U.S. House of Representatives 2025-11-19 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I 119th CONGRESS 1st Session H. R. 6130 IN THE HOUSE OF REPRESENTATIVES November 19, 2025 Mr. Buchanan (for himself and Mr. Tonko ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend title XVIII of the Social Security Act to provide for Medicare coverage of blood-based dementia screening tests. 1. Short title This Act may be cited as the Alzheimer’s Screening and Prevention Act of 2025 or the ASAP Act . 2. Medicare coverage of Alzheimer’s disease and related dementias early detection screening tests (a) Coverage Section 1861 of the Social Security Act ( 42 U.S.C. 1395x ) is amended— (1) in subsection (s)(2)— (A) in subparagraph (JJ), by striking the semicolon at the end and inserting ; and ; and (B) by adding at the end the following new subparagraph: (KK) Alzheimer’s disease and related dementias early detection screening tests (as defined in subsection (nnn)); ; and (2) by adding at the end the following new subsection: (nnn) Alzheimer’s disease and related dementias early detection screening tests The term Alzheimer’s disease and related dementias early detection screening test means a test furnished to an individual for the detection of the pre-symptomatic and early stage of Alzheimer’s disease or related dementias on or after January 1, 2028, that— (1) is cleared under section 510(k), classified under section 513(f)(2), or approved under section 515 of the Federal Food, Drug, and Cosmetic Act; and (2) is— (A) a genomic sequencing blood or blood product test; or (B) such other equivalent test, including a single-analyte test, blood test analysis of cell-free nucleic acids, multiplex panel test, whole genome sequencing, protein expression, whole exome, whole transcriptome, and medical imaging (which are based on blood, blood products, tissue, urine or other biospecimen), as the Secretary determines appropriate in providing results comparable to those obtained with a test described in subparagraph (A). . (b) Payment Section 1833(h)(1)(A) of the Social Security Act ( 42 U.S.C. 1395l(h)(1)(A) ) is amended by inserting Alzheimer’s disease and related dementias early detection screening tests under section 1861(nnn) and after including .
Loading intelligence layer…